Rabi Hanna, MD

The chairman of the Division of Pediatric Hematology & Oncology and BMT at Cleveland Clinic Children's.

Articles by Rabi Hanna, MD

Rabi Hanna, MD, on Practical Considerations for Integrating Gene Therapy

December 15th 2025

The chairman of the Division of Pediatric Hematology & Oncology and BMT at Cleveland Clinic Children's discussed learnings from the institutions integration of gene therapy for sickle cell disease.

Evaluating Gene Editing Therapy Reni-Cel for Severe Sickle Cell Disease

ByRabi Hanna, MD,Noah Stansfield

December 14th 2025

Rabi Hanna, MD, the chairman of the Division of Pediatric Hematology & Oncology and BMT at Cleveland Clinic Children's, discussed results from the phase 1/2 RUBY trial.

Rabi Hanna, MD, on Evaluating Gene Editing Therapy Reni-Cel for Severe Sickle Cell Disease

ByRabi Hanna, MD,Noah Stansfield

December 9th 2025

The chairman of the Division of Pediatric Hematology & Oncology and BMT at Cleveland Clinic Children's discussed results from the phase 1/2 RUBY trial he presented at ASH 2025.

Latest Updated Articles

Evaluating Gene Editing Therapy Reni-Cel for Severe Sickle Cell Disease
Published: December 14th 2025 | Updated:

Rabi Hanna, MD

Articles by Rabi Hanna, MD

Rabi Hanna, MD, on Practical Considerations for Integrating Gene Therapy

Evaluating Gene Editing Therapy Reni-Cel for Severe Sickle Cell Disease

Rabi Hanna, MD, on Evaluating Gene Editing Therapy Reni-Cel for Severe Sickle Cell Disease

Latest Updated Articles

Trending on CGTlive®

Integrating Gene Therapy into Clinical Care for Hemophilia B

CGTLive®’s Weekly Rewind – January 23, 2026

Jeffrey Goldberg, MD, PhD, on the Potential of Cell and Gene Therapy in Glaucoma